Biodesix, Inc.
NASDAQ:BDSXMedical - Diagnostics & Research
+$2.04 today
- Market cap
- $68.38M
- Beta
- 0.59
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$3.31
Volume 0.17M
Average 0.06M
BDSX Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Biodesix, Inc.NASDAQ: BDSX
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns negative
Q1 FY2026 accounts receivables was -$488K, compared with $904K a year earlier. Trailing-twelve-month accounts receivables was -$1.92M. Over 3 fiscal years it compounded at -29.3% a year.
Context
- Accounts receivables amounted to 0.6% of revenue in FY2025, down 1.9 pp from a year earlier.
- Accounts receivables grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly accounts receivables holds near -$488K or moves back toward the trailing-twelve-month quarterly average of -$480.75K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- (531K) USD
- Year-over-year change
- +70.7%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (531K) | +70.7% |
| FY2024 | 2024-12-31 | (1.81M) | +61.6% |
| FY2023 | 2023-12-31 | (4.72M) | -214.3% |
| FY2022 | 2022-12-31 | (1.5M) | -113.1% |
| FY2021 | 2021-12-31 | 11.45M | — |
Accounts Receivables vs competitors
How BDSX compares with its peers on the latest reported figures
- BDSX's LTM Mar 2026 accounts receivables of $1.92M is the 2nd largest of the 5 companies compared; the peer median is $323K.
- Its year-over-year change of -233.8% is the lowest of 2, against a peer median of -49.3%.
- Accounts receivables amounts to 2.0% of revenue for BDSX, versus a peer median of 32.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $17.5M | — | — | 32.7% | |
| LTM Mar 2026 | $1.92M | -233.8% | -29.3% | 2.0% | |
| LTM Mar 2026 | $646K | -49.3% | +1.9% | — | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $0 | — | — | — |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding BDSX) | $323K | -49.3% | +1.9% | 32.7% | |
Competitors are the stored peer set for BDSX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (43.16M) | (65.45M) | (52.15M) | (42.93M) | (35.27M) |
| Depreciation & Amortization | 3.18M | 5.84M | 5.51M | 5.46M | 5.6M |
| Deferred Income Tax | (2.11M) | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.94M | 5.96M | 5.37M | 6.64M | 4.14M |
| Change in Working Capital | 4.59M | (4.34M) | 11.3M | (21.67M) | 334K |
| Accounts Receivables | 11.45M | (1.5M) | (4.72M) | (1.81M) | (531K) |
| Inventory | 7.43M | 906K | 166K | 22K | 0 |
| Accounts Payables | (7.43M) | (773K) | 513K | 1.64M | 0 |
| Other Working Capital | (6.86M) | (2.98M) | 15.34M | (21.52M) | 865K |
| Other Non-Cash Items | 4.33M | 13.01M | 7.09M | 3.86M | 1.92M |
| Operating Cash Flow | (28.22M) | (44.97M) | (22.87M) | (48.65M) | (23.27M) |
| Capital Expenditures | (2.55M) | (3.53M) | (23.06M) | (3.23M) | (403K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (306K) | (236K) | (143K) | (210K) | (144K) |
| Investing Cash Flow | (2.55M) | (3.53M) | (23.06M) | (3.44M) | (403K) |
| Debt Repayment | (15.35M) | 16.5M | 9.95M | (51K) | 9.98M |
| Common Stock Issued | 16.34M | 59.54M | 28.13M | 55.63M | 7.82M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 269K | (17.15M) | (8.95M) | (3.52M) | (1.38M) |
| Financing Cash Flow | 1.26M | 58.88M | 29.13M | 52.05M | 16.42M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (29.51M) | 10.38M | (16.8M) | (39K) | (7.26M) |
| Free Cash Flow | (30.77M) | (48.51M) | (45.93M) | (51.88M) | (23.67M) |
Biodesix, Inc.
NASDAQ:BDSX
Intrinsic Alpha fair value
Locked
Current Price
$8.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.